What are the cardinal motor features of Parkinson disease?

The core motor feature is bradykinesia (slowness of movement), occurring together with rest tremor and/or rigidity; postural and gait changes appear as the disease progresses.

Is Parkinson disease only a movement disorder?

No. Although defined by its motor features, Parkinson disease also involves many non-motor symptoms such as loss of smell, constipation, sleep disturbance, and mood and cognitive changes, some of which can precede the motor signs.

Parkinson Disease

Parkinson disease is a common progressive neurodegenerative movement disorder defined clinically by bradykinesia together with rest tremor and/or rigidity, and pathologically by loss of dopaminergic neurons in the substantia nigra and the accumulation of alpha-synuclein in Lewy bodies. Beyond its motor features it involves a wide range of non-motor symptoms that can precede the movement disorder by years.

Leia teema tööriistaga PaperMindPeagiFind papers & topics

Tools & resources

Laadi slaidid alla

Learn & explore

VideoPeagi

Definition

Parkinson disease is a progressive neurodegenerative disorder characterised clinically by bradykinesia with rest tremor and/or rigidity, and pathologically by degeneration of dopaminergic neurons in the substantia nigra pars compacta and the deposition of aggregated alpha-synuclein in Lewy bodies and Lewy neurites.

Scope

This topic covers Parkinson disease as a clinical and biological entity: its cardinal motor features, the underlying nigral dopaminergic loss and alpha-synuclein pathology, the staged spread of Lewy pathology, its non-motor spectrum, and its epidemiology. It is a reference overview and does not provide diagnostic protocols or treatment guidance.

Core questions

How does nigral dopaminergic loss produce the cardinal motor features?
How does alpha-synuclein pathology spread through the nervous system?
Why do non-motor symptoms often precede motor symptoms?
How can the disease be distinguished from other parkinsonian syndromes?

Key concepts

Bradykinesia, rest tremor, and rigidity
Substantia nigra dopaminergic loss
Alpha-synuclein and Lewy bodies
Non-motor symptoms
REM sleep behaviour disorder as a prodrome
Differentiation from atypical parkinsonism

Key theories

Synucleinopathy and Lewy pathology: Parkinson disease is a synucleinopathy in which aggregated alpha-synuclein forms Lewy bodies and Lewy neurites; the loss of nigrostriatal dopaminergic neurons that accompanies this pathology underlies the dopamine deficiency responsible for the motor syndrome.
Braak staging of spread: Pathological staging schemes propose that alpha-synuclein pathology spreads in a caudo-rostral pattern, often beginning in the lower brainstem and olfactory structures before reaching the midbrain and cortex, offering a framework for why some non-motor symptoms appear before motor signs.

Mechanisms

Parkinson disease involves progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, depleting striatal dopamine and disrupting basal ganglia motor circuits to produce bradykinesia, rigidity, and rest tremor. The disease is a synucleinopathy: aggregated alpha-synuclein accumulates as Lewy bodies and neurites, and staging schemes describe a stereotyped spread of this pathology through the nervous system that can affect brainstem, olfactory, and autonomic structures before the midbrain, helping to explain why non-motor features such as hyposmia, constipation, and REM sleep behaviour disorder often precede the motor syndrome (Bloem et al., 2021; Dugger & Dickson, 2017).

Clinical relevance

Parkinson disease is a leading cause of neurological disability, and understanding its dopaminergic and alpha-synuclein pathology underpins how clinicians and researchers recognise its motor and non-motor features and distinguish it from related parkinsonian syndromes. This entry describes how the disease is defined and studied; it is not a basis for individual diagnosis or treatment decisions.

Epidemiology

Parkinson disease is the second most common neurodegenerative disorder after Alzheimer disease and one of the fastest-growing in terms of prevalence, rising with age and projected to increase substantially as populations age. Its prevalence is somewhat higher in men, and both genetic and environmental factors contribute to risk (Bloem et al., 2021).

History

James Parkinson described the disorder in his 1817 essay on the shaking palsy, and Jean-Martin Charcot later refined its clinical characterisation and attached Parkinson's name. The twentieth century established the central role of nigrostriatal dopamine loss, and the identification of alpha-synuclein as the principal component of Lewy bodies reframed the disease as a synucleinopathy, while staging schemes and revised clinical criteria sharpened its diagnosis (Bloem et al., 2021; Postuma et al., 2015).

Debates

Does Parkinson disease begin outside the brain?: Observations that pathology may appear early in the olfactory system and enteric nervous system have prompted debate over whether alpha-synuclein pathology can originate peripherally and spread to the brain, with implications for how the disease is conceptualised and staged.

Key figures

James Parkinson
Heiko Braak
Bastiaan Bloem
Ronald Postuma

Seminal works

bloem-2021
postuma-2015
dugger-dickson-2017

Frequently asked questions

What are the cardinal motor features of Parkinson disease?: The core motor feature is bradykinesia (slowness of movement), occurring together with rest tremor and/or rigidity; postural and gait changes appear as the disease progresses.
Is Parkinson disease only a movement disorder?: No. Although defined by its motor features, Parkinson disease also involves many non-motor symptoms such as loss of smell, constipation, sleep disturbance, and mood and cognitive changes, some of which can precede the motor signs.